SIGA TechnologiesSIGA
About: SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
Employees: 45
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0.63% more ownership
Funds ownership: 48.47% [Q4 2024] → 49.1% (+0.63%) [Q1 2025]
7% less repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 59
9% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 23
3% less funds holding
Funds holding: 170 [Q4 2024] → 165 (-5) [Q1 2025]
8% less capital invested
Capital invested by funds: $208M [Q4 2024] → $192M (-$15.8M) [Q1 2025]
22% less call options, than puts
Call options by funds: $621K | Put options by funds: $792K
100% less funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 0 (-1) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for SIGA.
Financial journalist opinion









